Efficacy and safety of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis
| Autor: | Vamsi P. Guntur, Ryan M. Dunn, Yeshai T. Dollin, Joshua L. Denson, Laurie A. Manka, Matthew Strand, Michael E. Wechsler |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Pulmonary and Respiratory Medicine
Adult Male medicine.medical_specialty Immunology Antibodies Monoclonal Humanized 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Reslizumab Adrenal Cortex Hormones Eosinophilic Eosinophilia medicine Immunology and Allergy Humans 030212 general & internal medicine Anti-Asthmatic Agents Anti-neutrophil cytoplasmic antibody business.industry Granulomatosis with Polyangiitis Middle Aged Benralizumab medicine.disease Dermatology Treatment Outcome 030228 respiratory system chemistry Prednisone Female medicine.symptom Interleukin-5 Granulomatosis with polyangiitis business Vasculitis Mepolizumab medicine.drug |
| Zdroj: | Annals of allergy, asthmaimmunology : official publication of the American College of Allergy, Asthma,Immunology. 126(6) |
| ISSN: | 1534-4436 |
| Popis: | Eosinophilic granulomatosis with polyangiitis (EGPA), a rare vasculitis with substantial morbidity, is characterized by asthma, eosinophilia, sinusitis, pulmonary infiltrates, neuropathy, positivity for antineutrophil cytoplasmic antibody, and multiorgan vasculitis. Although treatment options previously included corticosteroids and immunosuppressants, anti-interleukin 5 therapies have gained interest in EGPA treatment. Mepolizumab was approved for and recently benralizumab was found to have safety and efficacy in EGPA.To determine the safety and efficacy of reslizumab in EGPA.In this open-label, pilot study, we evaluated the safety and efficacy of intravenous reslizumab (3 mg/kg) in EGPA in 10 subjects. Oral corticosteroid dose, adverse events, exacerbations, symptom control, disease activity, blood markers, and lung function were evaluated before, during, and after 7 monthly reslizumab treatments.Reslizumab was tolerated and resulted in a significant reduction in daily oral corticosteroid (P.05). Of the 10 subjects, 3 experienced an EGPA exacerbation during the treatment. One had a severe adverse event, requiring removal from the study.Yielding similar results to other anti-interleukin 5 biologic medications, reslizumab is generally a safe and effective treatment for EGPA that warrants further study.ClinicalTrials.gov Identifier: NCT02947945. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|